Summary
Dorian Haskard was an undergraduate at Oxford University before moving to The Middlesex Hospital Medical School and subsequently into a range of clinical and research posts in London and the US. In 1987 he was awarded a Wellcome Trust Senior Clinical Fellowship at UMDS, Guy's Hospital. Following this he was appointed to Senior Clinical Lectureship at the Royal Postgraduate Medical School, Hammersmith Hospital, being promoted to Reader and then to Professor in 1995.
Professor Haskard has previously held the following leadership positions at Imperial College: British Heart Foundation Sir John McMichael Chair of Cardiovascular Medicine (1995-2016); Head of the Vascular Sciences Section within the National Heart and Lung Institute (2014-2017); Head of Division of Immunology and Inflammation in the Department of Medicine (2010-2017); and Head of the Division of Clinical Cardiovascular Science (2017-2018).
Professor Haskard has given numerous prestigious national and international lectures and is member of a number of learned societies and funding charities. Notably he was Chairman of the Arthritis Research Campaign Fellowship Committee (2000-2005) and Chairman of the British Atherosclerosis Society (2008-2010). He is President of the International Society for Behçet’s Disease (2016-2020), and serves on the National Anti-Doping Panel (NADP). He was elected a Fellow of the Academy of Medical Science in 2001.
He has directly supervised 7 post-docs; 45 completed PhD students and many MSc, MRes and BSc students have performed projects within his personal research group at Imperial College.
The goal of Professor Haskard's research has been to achieve a greater understanding of the pathophysiology of inflammatory responses affecting the vascular system, with a view eventually to achieving more specific clinical diagnostic tests and therapies. Current work focuses on two main areas in relation to the biology of vascular inflammation, atherosclerosis and thrombosis: (i) mechanisms of macrophage and endothelial cell gene expression, with an emphasis on post-transcriptional RNA regulation, and (ii) the role of antibodies and complement.
Publications
Journals
Schafer CM, Martin-Almedina S, Kurylowicz K, et al., 2023, Cytokine-Mediated Degradation of the Transcription Factor ERG Impacts the Pulmonary Vascular Response to Systemic Inflammatory Challenge., Biorxiv
Khamis R, Hartley A, Caga-Anan M, et al., 2022, A monoclonal autoantibody against a cryptic epitope on tissue-adherent low-density lipoprotein for molecular imaging in atherosclerosis, Jacc: Cardiovascular Imaging, Vol:15, ISSN:1876-7591
Kaura A, Hartley A, Panoulas V, et al., 2022, Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: a cohort study, Plos Medicine, Vol:19, ISSN:1549-1277
Hartley A, Pradeep M, Van den Berg V, et al., 2022, Depletion of homeostatic antibodies against malondialdehyde-modified low-density lipoprotein correlates with adverse events in major vascular surgery, Antioxidants, Vol:11, ISSN:2076-3921
Hartley A, Khamis R, Al-Lamee R, et al., 2021, The placebo-controlled effect of percutaneous coronary intervention on exercise induced changes in anti- malondialdehyde-LDL antibody levels in stable coronary artery disease: a substudy of the ORBITA Trial, Frontiers in Cardiovascular Medicine, Vol:8, ISSN:2297-055X